Review Article
Treatment of Febrile Neutropenia and Prophylaxis in Hematologic Malignancies: A Critical Review and Update
Table 2
Initial risk assessment for febrile neutropenic patients (adapted from NCCN guideline) [
7].
| Low risk (score > 21 on the MASCC risk score) OR: | High risk (score < 21 on the MASCC risk score) OR: |
| Outpatient status at time of development of fever | Inpatient status at time of development of fever | No associated acute comorbid illness | Significant medical comorbidity or clinically unstable | Anticipated short duration of severe neutropenia (less than 7 days) | Anticipated prolonged severe neutropenia (ANC < 100 cells and >7 days) | Good performance status (ECOG 01) | Hepatic insufficiency | No hepatic insufficiency | Renal insufficiency | No renal insufficiency | Pneumonia or other complex infections at clinical presentation | ā | Alemtuzumab | ā | Mucositis grade 3-4 |
|
|